6 mg vial: ৳ 103,953.82
Faricimab is a bispecific angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
- Macular edema secondary to retinal vein occlusion (RVO)
Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralization of both Ang-2 and vascular endothelial growth factor A (VEGF-A). Ang-2 causes vascular instability by promoting endothelial destabilization, pericyte loss, and pathological angiogenesis, thus potentiating vascular leakage and inflammation. It also sensitizes blood vessels to the activity of VEGF-A resulting in further vascular destabilization. Ang-2 and VEGF-A synergistically increase vascular permeability and stimulate neovascularization. By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability.
Geriatric Use: In the six Phase III clinical studies, approximately 58% (1,496/2,571 of patients randomized to
treatment with Faricimab were ≥65, years of age. No significant differences in efficacy or safety of Faricimab were seen with increasing age in these studies.
Renal Impairment: No dose adjustment is required in patients with renal impairment.
Hepatic Impairment: The safety and efficacy of Faricimab in patients with hepatic impairment has not been studied.